Status:
COMPLETED
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
COPD
Eligibility:
All Genders
40-75 years
Phase:
PHASE2
Brief Summary
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Eligibility Criteria
Inclusion
- Diagnosis of COPD
- Age 40-75 years
- Smoking history
Exclusion
- Other serious disease
- Allergy to QAB149
- Respiratory tract infection
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
686 Patients enrolled
Trial Details
Trial ID
NCT00098228
Start Date
July 1 2004
End Date
December 1 2004
Last Update
October 25 2011
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Pulmonary Research
Birmingham, Alabama, United States, 35294-0012
2
Diagnostic & Medical Clinic
Mobile, Alabama, United States, 36607
3
The University of South Alabama Medical Center
Mobile, Alabama, United States, 36688
4
Pulmonary Associates
Phoenix, Arizona, United States, 85006